Pulse Biosciences awards CTO Darrin Uecker 100,000 RSUs for AFib product development

PULSE BIOSCIENCES, INC.

Restricted stock units cover 100,000 shares of common stock, par value $0.001.
Grant vests in full on third anniversary of March 23, 2026 grant date.
Award made under Amended and Restated 2017 Equity Incentive Plan.
Compensation Committee granted for continued leadership in atrial fibrillation treatment product development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.